
2nd Edition of International Cancer and Precision Oncology Conference
🎯 Selling to this event's audience? Get a free tailored buyer list
Tell us your work email and our AI instantly builds a buyer list matched to 2nd Edition of International Cancer and Precision Oncology Conference — the best‑fit companies to target, the exact decision‑maker job titles, and the industry filters that fit what you sell.
About this event
2nd Edition of International Cancer and Precision Oncology Conference (ICPOC 2026)
The 2nd Edition of the International Cancer and Precision Oncology Conference (ICPOC 2026) is a premier global event dedicated to advancing knowledge and collaboration in the field of oncology. Held from November 23-25, 2026, this hybrid conference will take place in Singapore and online, offering a comprehensive platform for leading researchers, oncologists, healthcare professionals, and industry experts to discuss the latest breakthroughs in cancer research and treatment.
Event Overview
ICPOC 2026, themed "Oncology Nexus - Innovate, Collaborate, Conquer Cancer," will feature a dynamic program including keynote presentations from renowned experts, interactive oral and poster sessions, and panel discussions. The conference aims to foster collaboration and innovation among the global cancer community to tackle challenges in cancer research and treatment.
Dates and Location
- Dates: November 23-25, 2026
- Venue: Singapore (physical event) and Online (virtual participation)
Key Focus Areas
- Cancer Detection and Diagnosis
- Prevention and Epidemiology
- Case Reports
- Cancer Treatments
- Cancer Genetics and Genomics
- Palliative Care and Supportive Oncology
- Cancer Research and Clinical Trials
- Survivorship and Long-Term Care
Attendee Profile
The conference will attract a diverse range of attendees including:
- Leading researchers and clinicians in oncology
- Healthcare professionals and industry experts
- Academic institutions and research organizations
- Biotechnology and pharmaceutical companies
- Government and non-profit organizations focused on cancer research and patient care
Geographic Reach
ICPOC 2026 has a global audience reach, with participants expected from various countries. The physical event in Singapore will particularly draw attendees from Asia-Pacific, while the online component will facilitate worldwide participation.
Estimated Attendance
While specific numbers are not provided, the conference's hybrid format and global focus suggest a substantial turnout of researchers, clinicians, and industry professionals. The inclusion of both physical and virtual participation options is likely to enhance overall attendance.
Sample Buyer Companies and Job Profiles
| Priority | Company | Website | Best Title to Target | Why This is a Good Buyer Fit |
|---|---|---|---|---|
| 1 | Roche Holding Ltd. | https://www.roche.com | Oncology Research Director | Global leader in oncology research and treatment development. |
| 2 | Bristol-Myers Squibb Company | https://www.bms.com | Director of Clinical Trials | Major player in cancer immunotherapy and clinical research. |
| 3 | Illumina, Inc. | https://www.illumina.com | Genomics Research Manager | Leader in genomics and diagnostic solutions for cancer. |
| 4 | MD Anderson Cancer Center | https://www.mdanderson.org | Cancer Research Director | Prominent cancer research and treatment institution. |
| 5 | Novartis Pharmaceuticals Corporation | https://www.novartis.com | Oncology Product Development Manager | Global pharmaceutical company with a focus on oncology. |
| 6 | Foundation Medicine, Inc. | https://www.foundationmedicine.com | Director of Precision Oncology | Specialized in genomic profiling and precision cancer treatment. |
| 7 | Genentech, Inc. | https://www.genentech.com | Senior Oncology Research Scientist | Leading biotechnology company in oncology research. |
| 8 | Memorial Sloan Kettering Cancer Center | https://www.mskcc.org | Cancer Care Services Director | World-renowned cancer research and treatment center. |
| 9 | Pfizer Inc. | https://www.pfizer.com | Oncology Clinical Development Director | Global pharmaceutical leader with extensive oncology portfolio. |
| 10 | Thermo Fisher Scientific | https://www.thermofisher.com | Life Sciences Research Director | Provides advanced diagnostic and research tools for oncology. |
| 11 | AstraZeneca Pharmaceuticals LP | https://www.astrazeneca.com | Global Oncology Marketing Director | Major pharmaceutical company focused on oncology innovation. |
| 12 | City of Hope National Medical Center | https://www.cityofhope.org | Cancer Research Institute Director | Comprehensive cancer center dedicated to research and treatment. |
| 13 | Abbott Laboratories | https://www.abbott.com | Diagnostic Solutions Director | Leader in diagnostic technologies for cancer detection. |
| 14 | Johnson & Johnson Services, Inc. | https://www.jnj.com | Oncology Business Development Manager | Global healthcare leader with a strong oncology division. |
| 15 | University of Texas MD Anderson Cancer Center | https://www.mdanderson.org | Cancer Prevention Research Director | Pioneering research in cancer prevention and treatment. |
| 16 | Merck & Co., Inc. | https://www.merck.com | Director of Oncology Research | Leading pharmaceutical company in cancer immunotherapy. |
| 17 | Stanford Cancer Center | https://cancer.stanford.edu | Cancer Clinical Trials Director | Academic medical center focused on innovative cancer care. |
| 18 | Biogen Idec Ltd. | https://www.biogen.com | Oncology and Hematology Medical Director | Biotechnology company expanding into oncology research. |
| 19 | University of Pennsylvania Perelman School of Medicine | https://www.med.upenn.edu | Cancer Research Program Director | Leading academic institution in cancer research and education. |
| 20 | Harvard T.H. Chan School of Public Health | https://www.hsph.harvard.edu | Cancer Epidemiology Director | Renowned for public health research, including cancer epidemiology. |
Key Focus Areas & Buyer Engagement
The conference emphasizes breakthroughs in immuno-oncology, molecular biology, cancer immunotherapy, early detection, diagnostics, prevention strategies, and more. Buyers and attendees will engage through networking events, presentations, and discussions aimed at fostering collaboration and innovation in cancer research and treatment.
Recommendation
ICPOC 2026 is highly recommended for companies and organizations involved in oncology research, treatment development, diagnostic solutions, and precision oncology. The hybrid format offers flexibility, while the global reach ensures exposure to a wide audience of key stakeholders in the cancer community.
Contact and Registration
For more information and to register, visit the official website: https://cancer.miconferences.com/. Early registration closes on June 30, 2026, and the first phase of abstract submission closes on June 29, 2026.
Data sheet
| Event Name | 2nd Edition of International Cancer and Precision Oncology Conference (ICPOC 2026) |
| Event Date | November 23–25, 2026 |
| Event Status | Upcoming |
| Venue | Village Hotel Changi, 1 Netheravon Rd, Singapore 508502; hybrid participation also listed as Singapore and Online |
| City | Singapore |
| State / Region | Singapore |
| Country | Singapore |
| Organizer | Miconferences |
| Official Event Website | cancer.miconferences.com |
| Event Type | Hybrid international scientific conference |
| Primary Category | Medical & Pharma |
| Secondary Applicable Categories | Science & Research, Wellness, Health & Fitness |
| Audience Reach | Global, with hybrid online participation and international scientific reach |
| Estimated Attendance / Expected Footfall | Attendance figure not publicly confirmed by the organizer. |
| Attendance Data Reliability | Low for headcount; high for date, theme, venue format, and topic verification from official website |
| Main Purpose of Event | To advance oncology knowledge, precision medicine collaboration, research exchange, and clinical innovation across the global cancer community |
ICPOC 2026 is a hybrid international oncology conference focused on cancer research, precision oncology, immuno-oncology, diagnostics, treatment innovation, and survivorship. The official program positioning emphasizes scientific exchange through keynote talks, oral and poster presentations, panel discussions, and networking sessions for researchers, clinicians, and healthcare stakeholders.
This event matters because it sits at the intersection of clinical care, translational research, academic collaboration, and therapeutic innovation. It is relevant for organizations seeking oncology partnerships, clinical trial insight, medical education, research visibility, and access to a specialized global audience active in cancer detection, genomics, prevention, supportive care, and treatment development.
| Buyer / Attendee Segment | Typical Organizations | Buying Role or Influence | Relevance to Exhibitors / Suppliers |
|---|---|---|---|
| Clinical oncology leaders | Hospitals, cancer centers, academic medical centers | Evaluate therapies, pathways, diagnostics, and clinical evidence | High relevance for pharma, diagnostics, medtech, and research suppliers |
| Precision medicine / genomics teams | Genomics labs, molecular pathology labs, research institutes | Influence test selection, sequencing platforms, bioinformatics tools | Strong for omics, laboratory automation, informatics, and data suppliers |
| Hospital procurement teams | Hospitals, health systems, specialty clinics | Purchase devices, consumables, lab services, software, and services | Useful for medtech, lab, digital health, and service vendors |
| Clinical research and trial teams | CROs, sponsors, hospitals, academic trial units | Select trial partners, technology, data capture, and site capabilities | High relevance for CROs, eClinical tools, and patient recruitment vendors |
| Research scientists and principal investigators | Universities, institutes, cancer centers | Drive technology adoption, publication, and collaborations | Strong fit for research tools, reagents, and analytics suppliers |
| Oncology pharmacy leaders | Cancer hospitals, specialty pharmacies, integrated delivery networks | Influence drug selection, formulary, handling, and support services | Relevant for pharma services, cold chain, and medication systems |
| Public health / policy stakeholders | Government health agencies, cancer programs, regulators | Shape screening, guideline adoption, funding, and program design | Useful for health policy, population screening, and innovation partners |
| Medical education / KOL network leaders | Universities, societies, conference organizers | Influence CME/CPD, speaker selection, and educational partnerships | Relevant for education sponsors, journals, and event partners |
| Medical device and diagnostics buyers | Hospitals, reference labs, distributors | Evaluate platforms, tests, equipment, and service contracts | High relevance for diagnostic, imaging, pathology, and lab vendors |
| Industry sponsors and biotech decision-makers | Biopharma, biotech, research tool firms | Seek partnerships, scientific visibility, and pipeline intelligence | Strong for sponsorship, collaboration, and lead generation |
| Geographic Area | Likely Attendee Origin | Buyer Concentration | Notes |
|---|---|---|---|
| Host city: Singapore | Local hospitals, universities, biotech, and healthcare professionals | High | Singapore is a major APAC medical and research hub with strong conference draw |
| Host region: Southeast Asia | Attendees from Malaysia, Indonesia, Thailand, Philippines, Vietnam, and nearby markets | High | Regional oncology, diagnostics, and public health stakeholders are likely |
| Nearby business hubs | APAC headquarters teams, distributors, and life sciences commercial teams | Medium-High | Good for regional partnership development and channel outreach |
| National reach | Singapore-based clinicians, researchers, public health professionals, and suppliers | High | Hybrid format supports broader domestic participation |
| International reach | Global oncology researchers, clinicians, and healthcare vendors | High | Official website positions the event as a premier global conference |
| Reach Level | Assessment | Explanation |
|---|---|---|
| Global | Primary classification | The official site describes the conference as a premier global event with hybrid access for international participation. |
| Buyer Company / Organization | Buyer Type | Why It Is Relevant | Website | Best Job Titles to Target | Evidence Level |
|---|---|---|---|---|---|
| National Cancer Centre Singapore | Cancer center / clinical buyer | Direct oncology care, research, and precision medicine relevance | nccs.com.sg | Medical Director, Head of Oncology, Research Director, Procurement Manager | Strong Market Fit, Attendance Not Confirmed |
| Singapore General Hospital | Hospital buyer | Large tertiary hospital with oncology, diagnostics, and research programs | sgh.com.sg | Director of Clinical Services, Head of Procurement, Lab Manager, CIO | Strong Market Fit, Attendance Not Confirmed |
| National University Hospital | Academic medical center buyer | Oncology research, trials, and hospital procurement are highly relevant | nuh.com.sg | Director of Procurement, Oncology Chair, Clinical Trials Manager | Strong Market Fit, Attendance Not Confirmed |
| A*STAR | Research organization | Translational research, genomics, and scientific collaboration buyer | astar.edu.sg | Principal Investigator, Research Director, Lab Head, Program Manager | Strong Market Fit, Attendance Not Confirmed |
| Duke-NUS Medical School | Medical school / research buyer | Clinical research, oncology education, and scientific networking relevance | duke-nus.edu.sg | Dean, Research Director, Professor, Clinical Trial Lead | Strong Market Fit, Attendance Not Confirmed |
| National Cancer Institute (United States) | Government / research buyer | Global cancer research benchmark organization; useful for policy and partnership targeting | cancer.gov | Program Director, Grants Manager, Research Officer, Scientific Program Lead | Strong Market Fit, Attendance Not Confirmed |
| Cancer Research UK | Research / nonprofit buyer | Funding, awareness, research collaborations, and scientific exchange | cancerresearchuk.org | Research Partnerships Director, Medical Director, Scientific Affairs Lead | Strong Market Fit, Attendance Not Confirmed |
| Mayo Clinic | Hospital / research buyer | Precision oncology, clinical innovation, and trial operations are highly relevant | mayoclinic.org | Oncology Chair, Research Director, Procurement Lead, Clinical Trial Manager | Strong Market Fit, Attendance Not Confirmed |
| MD Anderson Cancer Center | Cancer center / clinical buyer | Leading oncology center for research, therapeutics, and diagnostics | mdanderson.org | Vice President Oncology, Lab Director, Clinical Research Manager, Sourcing Lead | Strong Market Fit, Attendance Not Confirmed |
| Memorial Sloan Kettering Cancer Center | Cancer center / clinical buyer | Advanced oncology, research, and precision medicine adoption | mskcc.org | Oncology Director, Clinical Development, Lab Operations, Procurement Director | Strong Market Fit, Attendance Not Confirmed |
| GSK | Pharmaceutical buyer / sponsor | Oncology pipeline, medical affairs, and scientific partnership relevance | gsk.com | Medical Affairs Director, Oncology Strategy Lead, Partnering Manager | Strong Market Fit, Attendance Not Confirmed |
| Roche | Diagnostics / pharma buyer | Diagnostics, precision oncology, and biomarker strategy are aligned | roche.com | Business Development Director, Medical Affairs Lead, Diagnostics Head | Strong Market Fit, Attendance Not Confirmed |
| Thermo Fisher Scientific | Life sciences tools buyer / supplier | Research tools, diagnostics workflows, and lab technologies are relevant | thermofisher.com | Sales Director, Product Manager, Scientific Affairs, Channel Manager | Strong Market Fit, Attendance Not Confirmed |
| Illumina | Genomics buyer / supplier | Sequencing, oncology genomics, and biomarker workflows align closely | illumina.com | Genomics Director, Product Marketing, Market Development, Partnerships | Strong Market Fit, Attendance Not Confirmed |
| Tempus | Precision medicine / data buyer | AI-enabled oncology diagnostics and data partnerships are highly relevant | tempus.com | Business Development, Clinical Partnerships, Data Science Leader | Strong Market Fit, Attendance Not Confirmed |
| Pfizer | Pharmaceutical buyer / sponsor | Oncology drug development and scientific collaboration relevance | pfizer.com | Oncology Medical Director, Alliance Manager, Clinical Operations Lead | Strong Market Fit, Attendance Not Confirmed |
| Priority | Job Title / Function | Department | Seniority Level | Why This Role Matters |
|---|---|---|---|---|
| 1 | Chief Medical Officer / Oncology Director | Clinical leadership | C-level / VP | Owns clinical strategy, adoption of treatments, and research collaboration |
| 2 | Head of Oncology / Medical Affairs Director | Medical affairs | Director / VP | Influences evidence review, scientific exchange, and partnerships |
| 3 | Director of Clinical Research / Clinical Trials Manager | Research / clinical operations | Manager / Director | Selects research tools, collaborators, and trial infrastructure |
| 4 | Principal Investigator / Professor | Research / academia | Senior / academic leader | Drives publication, collaborations, and scientific procurement decisions |
| 5 | Director of Pathology / Molecular Pathology Lead | Diagnostics | Director / Head | Key influencer for diagnostics, biomarker, and sequencing solutions |
| 6 | Procurement Manager / Strategic Sourcing Manager | Procurement / sourcing | Manager / Director | Purchases equipment, reagents, software, and services |
| 7 | CIO / IT Director / Digital Health Lead | IT / digital transformation | Director / C-level | Relevant for data platforms, AI, interoperability, and workflow tools |
| 8 | Lab Director / Lab Operations Manager | Laboratory operations | Manager / Director | Influences equipment, consumables, and lab automation purchases |
| 9 | Oncology Pharmacist / Pharmacy Director | Pharmacy | Director / Senior manager | Relevance for drug handling, supportive care, and formulary decisions |
| 10 | Program Manager / Scientific Affairs Manager | Programs / partnerships | Manager / Director | Coordinates collaborations, education, abstracts, and sponsorships |
| Priority | Apollo Industry | Why It Fits the Event | Best Buyer Use Case |
|---|---|---|---|
| 1 | Hospital & Health Care | Primary attendee base is hospitals, cancer centers, and clinics | Clinical leaders, procurement, and diagnostics buyers |
| 2 | Biotechnology | Precision oncology and translational science are core topics | Biomarkers, therapeutics, and R&D partners |
| 3 | Pharmaceuticals | Drug development, oncology pipelines, and medical affairs relevance | Partnership, scientific exchange, and sponsorship targeting |
| 4 | Medical Devices | Diagnostics, imaging, biopsy, and treatment technologies matter | Device buyers and clinical evaluation stakeholders |
| 5 | Research | Scientific conference with strong research participation | Principal investigators, lab heads, and research buyers |
| 6 | Biotechnology & Life Sciences Tools | Omics, assays, reagents, and platforms are highly relevant | Lab instruments, reagents, and workflow sales |
| 7 | Information Technology & Services | AI, analytics, data capture, and interoperability use cases | Digital health and software vendors |
| 8 | Government Administration | Public health policy and national cancer programs are relevant | Government health stakeholders and buyers |
| 9 | Education Management | Academic medicine and CME/CPD participation are strong | University programs and medical education buyers |
| 10 | Nonprofit Organization Management | Cancer foundations and advocacy groups often attend or partner | Program sponsorship and patient support initiatives |
| 11 | Market Research | Conference intelligence and scientific insight use cases | Insight, advisory, and audience analysis services |
| 12 | Events Services | Scientific conference ecosystem and partner management | Sponsorship sales and event operations |
| Metric | Figure | Status | Source / Basis | Notes |
|---|---|---|---|---|
| Estimated total footfall | Not publicly confirmed | Confirmed non-disclosed | Official website reviewed | Organizer does not publicly confirm attendance figure on the referenced page |
| Exhibitor count | Not publicly confirmed | Not disclosed | Official website reviewed | Conference appears primarily scientific; exhibitor totals not visible in source text |
| Buyer count | Not publicly confirmed | Not disclosed | Official website reviewed | No buyer directory or procurement attendance list located in provided source text |
| Speaker count | Not publicly confirmed | Not fully disclosed | Official website reviewed | The speaker page exists, but the provided source text does not enumerate a complete count |
| Sponsor count | Not publicly confirmed | Not disclosed | Official website reviewed | No sponsor list present in the supplied official text |
| Historical attendance | Not publicly confirmed | Unavailable | Official website reviewed | Prior-year attendance statistics were not provided in the supplied source text |
| Focus Area | Typical Buyer Need | Buyer Engagement Opportunity | Relevant Supplier Offering |
|---|---|---|---|
| Cancer detection and diagnosis | Earlier and more accurate identification of malignancy | Discuss screening tools, imaging, pathology, and biomarkers | Diagnostics, imaging, pathology, and biomarker solutions |
| Precision oncology | Targeted treatment and patient stratification | Position assays, companion diagnostics, and decision support | Genomics, data analytics, and clinical decision platforms |
| Cancer immunotherapy | New therapeutic approaches and trial evidence | Engage medical and scientific leaders on innovation | Pharma, biotech, and immuno-oncology support services |
| Clinical trials and research | Trial design, patient recruitment, and data management | Offer site support, eClinical tools, and study services | CRO, eCOA, EDC, and study operations services |
| Cancer genetics and genomics | Molecular insights for diagnosis and therapy selection | Target sequencing and bioinformatics stakeholders | Sequencing systems, panels, software, and interpretation tools |
| Palliative care and supportive oncology | Symptom control and quality-of-life improvement | Introduce support services, patient engagement tools, and care pathways | Supportive care programs, patient education, and care coordination tools |
| Survivorship and long-term care | Post-treatment monitoring and patient follow-up | Offer longitudinal care platforms and analytics | Remote monitoring, patient portals, and outcomes tools |
| Medical education and CPD | Accredited learning and knowledge exchange | Sponsor sessions, content, and speaker collaborations | Education sponsorships, journals, and event partnerships |
| Factor | Assessment | Explanation |
|---|---|---|
| Buyer relevance | Very High | The audience is highly aligned with healthcare, research, diagnostics, and oncology buying functions. |
| Decision-maker availability | High | Likely to attract senior clinicians, lab heads, research leaders, and procurement stakeholders. |
| Data collection potential | Medium | Good for speaker and committee intelligence; attendee list availability is limited in the supplied source text. |
| Apollo targeting potential | Very High | Clear industry, title, and geography filters can be built around hospitals, biotech, pharma, and research. |
| Geographic targeting potential | High | Singapore and APAC targeting are highly practical, with global participation possible via hybrid format. |
| Best outreach approach | Consultative, evidence-led, and partnership-oriented | Focus on scientific value, workflow improvement, and clinical outcomes rather than generic promotion. |
| Overall lead quality | High | Strong event for oncology-focused B2B outreach and stakeholder mapping. |
| Best use case | Account targeting, partner discovery, scientific sponsorship, and attendee list enrichment | Most valuable for oncology, diagnostics, and healthcare research vendors. |
| Limitations / risks | Limited public attendee visibility | No current-year attendee list or attendance figure was publicly confirmed in the supplied source text. |
| Filter Type | Recommended Filters | Purpose |
|---|---|---|
| Apollo industries | Hospital & Health Care; Biotechnology; Pharmaceuticals; Medical Devices; Research; Information Technology & Services; Government Administration; Education Management; Nonprofit Organization Management; Market Research | Capture the core attendee and buyer universe around oncology and precision medicine |
| Departments | Clinical, Research, Procurement, Operations, IT, Medical Affairs, Business Development, Partnerships | Align outreach to decision-making and influence centers |
| Seniority | Manager, Director, VP, CXO, Professor, Head of Department | Prioritize senior stakeholders with budget, research, or adoption authority |
| Job titles | Oncology Director, Medical Affairs Director, Research Director, Lab Director, Procurement Manager, Strategic Sourcing Manager, Clinical Trials Manager, Principal Investigator, Head of Pathology, CIO | Target titles most likely to influence purchasing, partnerships, or scientific evaluation |
| Geography | Singapore, Malaysia, Indonesia, Thailand, Philippines, Vietnam, India, Australia, United States, United Kingdom | Support local, regional, and global conference-based prospecting |
| Employee size | 51–200, 201–500, 501–1,000, 1,001–5,000, 5,001–10,000, 10,000+ | Cover biotech scale-ups, hospitals, universities, and major healthcare enterprises |
| Keywords | oncology, precision medicine, immuno-oncology, genomics, biomarker, clinical trial, molecular pathology, cancer research, diagnostics, translational research | Improve relevance and suppress unrelated healthcare records |
| Company type | Hospitals, academic medical centers, research institutes, biotech, pharma, diagnostics firms, government health agencies | Focus on organizations most likely to sponsor, attend, or buy |
Suggested Apollo Search Logic: (oncology OR “precision medicine” OR genomics OR biomarker OR “clinical trials” OR immuno-oncology) AND (hospital OR “medical center” OR biotechnology OR pharmaceuticals OR diagnostics OR research) AND (Director OR VP OR Head OR Manager OR Professor OR CMO OR CIO) with geography set to Singapore and APAC priority markets.
| Source | Type | What It Verified | Reliability |
|---|---|---|---|
| ICPOC 2026 Official Website | Official organizer / event website | Event title, dates, hybrid format, theme, topics, organizer, and confirmed committee/speaker organization names | High |
| Conference Page: About / Program / Speakers | Official event page sections | Scientific scope, attendee mix, CPD claims, and listed committee affiliations | High |
| Village Hotel Changi | Venue website | Venue identity and address validation for the physical meeting location | High |
| Supplied event description | User-provided reference text | Context on conference positioning, focus areas, and intended audience | Moderate |
Suitable for B2B attendee list building: yes, especially for oncology, precision medicine, diagnostics, research tools, and healthcare services prospecting. Public attendee and buyer lists were not confirmed in the supplied official source text.
🎯 Selling to this event's audience? Get a free tailored buyer list
Tell us your work email and our AI instantly builds a buyer list matched to 2nd Edition of International Cancer and Precision Oncology Conference — the best‑fit companies to target, the exact decision‑maker job titles, and the industry filters that fit what you sell.